What do systematic reviews say?

Rivastigmine vs placebo

Rivastigmine showed no clear difference in serious adverse events (excluding death) at 24 to 26 weeks compared with placebo (low certainty).

• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  OR 1.42 [0.9, 2.25]
  2 studies · 622 participants
  Low